Scientific Journals and Books

2025
Highly potent quinoxalinediones inhibit alpha-hemolysin and ameliorate Staphylococcus aureus lung infections

Shekhar A, Di Lucrezia R, Jerye K, Korotkov V S, Harmrolfs K, Rox K, Weich H A, Ghai I, Delhommel F, Becher I, Degenhart C, Fansa E, Unger A, Habenberger P, Klebl B, Lukat P, Schmelz S, Henke S, Borgert S, Lang J C, Sasse F, Diestel R, Richter C, Schneider-Daum N, Hinkelmann B, Niemz J, Lehr C M, Jansch L, Huehn J, Alm R, Savitski M, Welte T, Hesterkamp T, Sattler M, Winterhalter M, Blankenfeldt W, Medina E, Bilitewski U, Dinkel K and Bronstrup M. Cell Host Microbe. 2025; 33 (4): 560-572 e521. doi: 10.1016/j.chom.2025.03.006

The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigm

Hoffrogge R, Karachunskaya A, Heitmann N, Pedreiturria X, Kloster K, Bader V, Winklhofer K F, Hamacher M, Klebl B, Gold R, Dinkel K, Kleiter I and Faissner S. Front Immunol. 2025; 16 1554999. doi: 10.3389/fimmu.2025.1554999

Design and Synthesis of Pyridine-Based Pyrrolo[2,3-d]pyrimidine Analogs as CSF1R Inhibitors: Molecular Hybridization and Scaffold Hopping Approach

Cherukupalli S, Degenhart C, Habenberger P, Unger A, Eickhoff J, Hoff B H and Sundby E. Pharmaceuticals. 2025; 18 (6): doi: 10.3390/ph18060814

RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma

Egea-Rodriguez S, Varaljai R, Nordmann T M, Lubis R, Philip M, Rambow F, Roesch A, Flaig M, Horn S, Stoll R, Zhao F, Paschen A, Klebl B, Hickson I D, Schadendorf D, Mann M and Helfrich I. Clin Transl Med. 2025; 15 (1): e70094. doi: 10.1002/ctm2.70094

P2X7R antagonism suppresses long-lasting hyperexcitability following traumatic brain injury in mice

Alves M, de Diego-Garcia L, Vegliante G, Moreno O, Gil B, Ramos-Cabrer P, Mitra M, Fernandez Martin A, Menendez Mendez A, Wang Y, Ryzwesky Strogulsky N, Sun M, Melia C, Conte G, Plaza-Garcia S, Khalin I, Teng X, Plesnila N, Klebl B, Dinkel K, Hamacher M, Bhattarcharya A, Ceusters M, Palmer J, Loane D, Llop J, Henshall D and Engel T. Theranostics. 2025; 15 (4): 1399-1419. doi: 10.7150/thno.97254

2010
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer

Weiss J, Sos M L, Seidel D, Peifer M, Zander T, Heuckmann J M, Ullrich R T, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp L C, Balke-Want H, Ansen S, Rauh D, Baessmann I, Altmuller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun O T, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas R K. Sci Transl Med. 2010; 2 (62): 62ra93. doi: 10.1126/scitranslmed.3001451

A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitors

Scholz A K, Klebl B M, Morkel M, Lehrach H, Dahl A, Lange B M. Assay Drug Dev Technol. 2010; 8 (5): 571-580. doi: 10.1089/adt.2009.0260

Small-molecule inhibition of APT1 affects Ras localization and signaling

Dekker F J, Rocks O, Vartak N, Menninger S, Hedberg C, Balamurugan R, Wetzel S, Renner S, Gerauer M, Scholermann B, Rusch M, Kramer J W, Rauh D, Coates G W, Brunsveld L, Bastiaens P I, Waldmann H. Nat Chem Biol. 2010; 6 (6): 449-456. doi: 10.1038/nchembio.362